Back to top
more

Repligen (RGEN)

(Real Time Quote from BATS)

$133.34 USD

133.34
463,628

+10.74 (8.76%)

Updated Jul 16, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

LGND or RGEN: Which Is the Better Value Stock Right Now?

LGND vs. RGEN: Which Stock Is the Better Value Option?

LGND or RGEN: Which Is the Better Value Stock Right Now?

LGND vs. RGEN: Which Stock Is the Better Value Option?

Aniruddha Ganguly headshot

Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks

Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.

Repligen (RGEN) Down 0.4% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QGEN vs. RGEN: Which Stock Is the Better Value Option?

QGEN vs. RGEN: Which Stock Is the Better Value Option?

Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen

Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen

Sanghamitra Saha headshot

Profit From 5 Stocks Likely to Beat on Earnings

Bet on five stocks that are likely to outdo earnings estimates.

Why Repligen (RGEN) Might be Well Poised for a Surge

Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 45.46% and 5.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXEL or RGEN: Which Is the Better Value Stock Right Now?

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.

Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat

Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.

Benjamin Rains headshot

Should Growth Investors Buy this Cancer Screening Biotech Stock?

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

Intercept (ICPT) Concludes Enrollment in Study on NASH Drug

Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.

ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?

Is (RGEN) Outperforming Other Medical Stocks This Year?

3 Reasons Growth Investors Will Love Repligen (RGEN)

Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy

Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

Is (RGEN) Outperforming Other Medical Stocks This Year?

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 30.00% and 5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Reports Next Week: What to Expect

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH